Sanofi India Q1 FY27 Results: Revenue at ₹312.74 Crore, Net Profit at ₹45.14 Crore
Sanofi India reported Q1 FY27 results with total income from operations at ₹312.74 crore, down from ₹331.06 crore YoY. Net profit after tax rose to ₹45.14 crore from ₹41.57 crore. For the half-year, income was ₹643.80 crore and net profit was ₹86.71 crore. Basic EPS was ₹1.36.
The financial results provide key performance indicators for the quarter and half-year, which are material information for investors and stakeholders. The mixed performance warrants a medium impact assessment.
The results show a slight decrease in revenue but an increase in net profit, indicating a mixed financial performance. While profit growth is positive, the revenue dip warrants a neutral sentiment.
Sanofi India Limited has announced its financial results for the quarter and half-year ended June 30, 2026. The company reported a total income from operations of ₹312.74 crore for the quarter, a slight decrease from ₹331.06 crore in the same period last year.
The net profit after tax for the quarter stood at ₹45.14 crore, compared to ₹41.57 crore in the corresponding quarter of the previous year, marking an increase. Total comprehensive income for the period was ₹44.74 crore.
For the half-year ended June 30, 2026, total income from operations was ₹643.80 crore. The net profit after tax for the half-year was ₹86.71 crore, and total comprehensive income was ₹86.16 crore.
The company's paid-up equity share capital was ₹330.77 crore as of June 30, 2026. Reserves stood at ₹1,029.76 crore, and the Debt Equity Ratio was reported at 1.87.
Basic Earnings Per Share (EPS) for the quarter was ₹1.36, and diluted EPS was ₹0.92. These figures are not annualized for the quarters ended.
Sanofi India Limited has published these financial results in the Business Standard (English) and Sakal (Marathi) newspapers on August 5, 2026, as per SEBI regulations.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.